These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 39375281)

  • 1. Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History.
    Blauvelt A; Kallender H; Sturm D; Li Q; Ren H; Eichenfield LF
    Dermatol Ther (Heidelb); 2024 Nov; 14(11):3161-3174. PubMed ID: 39375281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies.
    Simpson EL; Kircik L; Blauvelt A; Kallender H; Sturm D; Wang M; Eichenfield LF
    Dermatol Ther (Heidelb); 2024 Aug; 14(8):2139-2151. PubMed ID: 38995504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
    Eichenfield LF; Simpson EL; Papp K; Szepietowski JC; Blauvelt A; Kircik L; Silverberg JI; Siegfried EC; Kuligowski ME; Venturanza ME; Kallender H; Ren H; Paller AS
    Am J Clin Dermatol; 2024 Jul; 25(4):669-683. PubMed ID: 38698175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy.
    Simpson EL; Kircik L; Blauvelt A; Kallender H; Kuo Y; Ren H; Sturm D; Eichenfield LF
    J Dermatol; 2023 Dec; 50(12):1523-1530. PubMed ID: 37830436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical anti-inflammatory treatments for eczema: network meta-analysis.
    Lax SJ; Van Vogt E; Candy B; Steele L; Reynolds C; Stuart B; Parker R; Axon E; Roberts A; Doyle M; Chu DK; Futamura M; Santer M; Williams HC; Cro S; Drucker AM; Boyle RJ
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD015064. PubMed ID: 39105474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.
    Blauvelt A; Kircik L; Papp KA; Simpson EL; Silverberg JI; Kim BS; Kwatra SG; Kuligowski ME; Venturanza ME; Wei S; Szepietowski JC
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):137-146. PubMed ID: 36066323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Silverberg JI; Wollenberg A; Reich A; Thaçi D; Legat FJ; Papp KA; Stein Gold L; Bouaziz JD; Pink AE; Carrascosa JM; Rewerska B; Szepietowski JC; Krasowska D; Havlíčková B; Kalowska M; Magnolo N; Pauser S; Nami N; Sauder MB; Jain V; Padlewska K; Cheong SY; Fleuranceau Morel P; Ulianov L; Piketty C;
    Lancet; 2024 Aug; 404(10451):445-460. PubMed ID: 39067461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies.
    Simpson EL; Bissonnette R; Chiesa Fuxench ZC; Kallender H; Sturm D; Ren H; Stein Gold LF
    J Dermatolog Treat; 2024 Dec; 35(1):2310633. PubMed ID: 38297490
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
    Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
    J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies.
    Bloudek L; Eichenfield LF; Silverberg JI; Joish VN; Lofland JH; Sun K; Augustin M; Migliaccio-Walle K; Sullivan SD
    Am J Clin Dermatol; 2023 Jan; 24(1):109-117. PubMed ID: 36264430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
    Hoy SM
    Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives.
    Eichenfield LF; Liu J; Marwaha S; Piercy J; Sturm D; Anderson P
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):685-696. PubMed ID: 38453811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
    Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Forman SB; Kuligowski ME; Kallender H; Sun K; Ren H; Simpson EL
    J Am Acad Dermatol; 2023 May; 88(5):1008-1016. PubMed ID: 36574595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
    Kim BS; Howell MD; Sun K; Papp K; Nasir A; Kuligowski ME;
    J Allergy Clin Immunol; 2020 Feb; 145(2):572-582. PubMed ID: 31629805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis.
    Chen Q; Cui L; Hu Y; Chen Z; Gao Y; Shi Y
    Heliyon; 2023 Nov; 9(11):e22014. PubMed ID: 38034798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
    Eichenfield LF; Stein Gold LF; Lynde C; Guenther L; Greenberger S; Chu CY; Ghodsi Z; Vlahos B; Sanders P; Cha A; Canosa JM
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):875-892. PubMed ID: 38546803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.